Using Semaglutide and Tirzepatide as benchmarks, we compare across multiple dimensionsweight loss efficacy, safety, titration strategy, baseline characteristics, etc.to assess which candidates truly have the potential to become strong competitors to these two already-approved blockbuster drugs in the future
This typically improves once weight stabilizes
No other approved or late-stage investigational compound does this
Two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials (LIPO-010 and LIPO-011) enrolled 816 HIV-infected patients with lipodystrophy
Mentias A, Desai MY, Aminian A et al (2024) Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity